TreeFrog Therapeutics secures $75m in Series B financing to advance a pipeline of Stem Cell-Derived cell therapies and deploy proprietary C-Stem™ technology in the USA & Japan
by
Excerpt Pursuant to securing $75 million in Series B funding, TreeFrog Therapeutics names Frederic Desdouits, PhD, as CEO and announces that co-founder Kevin Alessandri, PhD, is to relocate to Boston to drive TreeFrog’s expansion in the U.S. The funding was led by Bpifrance Large Venture, together with Leonard Green & Partners L.P., Bristol Myers Squibb […]
Bio-Thera Solutions Announces Commercialization and License Agreement for BAT1706, a Proposed Biosimilar Referencing Avastin® (Bevacizumab)
Excerpt Bio-Thera Solutions and Sandoz have entered a commercialisation and license agreement for BAT1706, a monoclonal antibody that is a proposed biosimilar referencing AVASTIN® (bevacizumab). Under the terms of the agreement, Bio-Thera will develop, manufacture and supply BAT1706 and Sandoz will market the bevacizumab biosimilar in markets covered by the agreement. Article Bio-Thera Solutions has […]
AbbVie and REGENXBIO Announce Eye Care Collaboration
Excerpt AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach […]
Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability
Excerpt I Peace is expanding its proprietary clinical-grade induced pluripotent stem cell (iPSC) banking service – first by improving accessibility across Japan through a collaboration with I’rom Group, and then expanding to global markets including the U.S. Leveraging an increased mass manufacturing capability and reduced costs with the development of a novel system, the company […]
FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke
Excerpt The two companies have entered a manufacturing agreement for NXL-001, under which FUJIFILM will be tasked with providing essential drug substance and drug product manufacturing under accelerated timelines at its manufacturing facility in College Station, Texas, for NeuExcell’s first in-human clinical studies. This will hopefully facilitate a possible treatment for patients suffering from ischemic […]
Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support the Development of Personalized Therapeutics
by
Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support the Development of Personalized Therapeutics Generate Life Sciences, the largest private newborn stem cell biorepository in the world, announced the establishment of its Good Manufacturing Practice (GMP) facility in La Jolla, California, to manufacture newborn stem cell biologics. This bolsters the company’s existing stem cell research […]
Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing
by
Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing Clinical-stage biopharmaceutical company Poseida Therapeutics has joined life sciences technology company Cellares Corporation’s Early Access Partnership Program (EAPP), making it the third organisation to participate. Through the program, Poseida gets visibility and access to Cellares’ Cell Shuttle and will help to advance its development, range […]
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
by
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement Belgium-based eTheRNA immunotherapies has established a collaboration and licence agreement with Ghent University for mRNA delivery with enhanced thermostability, biodegradability and safety. eTheRNA will receive worldwide commercialisation rights for the new generation of lipid nanoparticle (LNP) formulations co-developed with the university’s research group […]
Kintor Pharmaceutical Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa
by
Kintor Pharmaceutical Limited and Shanghai Fosun Pharmaceutical Development Ltd. have formed a licensing agreement in view of collaborating on the commercialisation of proxalutamide for the treatment of COVID-19 indication in India and 28 African countries (the “Collaboration Regions”). As part of this agreement, Fosun Pharma Development will have exclusive rights of registration and commercialisation of […]
Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs
by
As part of a new strategic collaboration with KAEDI Biotech Inc., Porton Biologics Ltd. will provide KAEDI with CMC services for CAR-T projects with its end-to-end CDMO platform, to help accelerate development. The results of the companies’ first project in collaboration, KD-025 CAR-T, have been published and there is an ongoing multi-centre clinical trial of […]
